AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
MAIA Biotechnology, Inc.
Video analysis: MAIA
All videosNo video analysis for this stock yet. Request one from our team.
News: MAIA
MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO
CHICAGO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today announced that Board member Ramiro Guerrero, JD, LL.M. has increased his ownership stake in the Company through open market purchases totaling approximately $252,284. A total of 185,078 shares of MAIA common stock were acquired by Mr. Guerrero between August 20, 2026, and September 10, 2026, at an average common stock price of $1.36. MAIA also announced that 73,000 shares of MAIA common stock were acquired by Founder and CEO Vlad Vitoc, M.D. on September 14, 2026, at an average common stock price of $1.37.
MAIA: Tiffany Wilding Says Labor Costs Are Easing, Supporting Fed Patience, ft. Tiffany Wilding
PIMCO economist Tiffany Wilding said labor markets are no longer a major source of inflation pressure, pointing to broad measures of nominal wage inflation that have been decelerating. She argued that AI, demographic shifts, aging, and retirements are changing labor dynamics and keeping wage pressures modest.
MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026
Next-generation divalent agents show increased anticancer activity in preclinical in vitro and in vivo models CHICAGO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today announced its presentation of a poster featuring its second-generation telomere-targeting anticancer drug candidates at the recent XXVI International Round Table on Nucleosides, Nucleotides and Nucleic Acids (IRT 2026) held in Barcelona, Spain.
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
New York, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechnology, Inc. (NYSE: MAIA). The research summary below is from a report commissioned by MAIA Biotechnology, Inc. and produced by Diamond Equity Research.
MAIA: High Bar For ECB Surprise, Alphabet CAPEX In Focus: 3 Minutes MLIV
Anna Edwards, Guy Johnson and Adam Linton break down today's key themes for analysts and investors on "Bloomberg: The Opening Trade." -------- More on Bloomberg Television and Markets Like this video?
MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial
90.5% interim disease control rate (DCR) observed with combination therapy Initial Part C efficacy observations align with previously reported THIO-101 clinical activity despite a more heavily pre-treated patient population CHICAGO, July 08, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced positive initial efficacy data from its Phase 2 THIO-101 clinical trial expansion, Part C, evaluating its lead candidate, ateganosine, a dual mechanism of action drug incorporating telomere targeting and immunogenicity, as a third-line (3L) therapy for patients with advanced non-small cell lung cancer (NSCLC). Initial data from the THIO-101 Part C 3L studies1 show a disease control rate (DCR) of 90.5% (19 out of 21 patients) in the efficacy evaluable population who had at least one tumor scan after starting treatment.
MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial
90. 5% interim disease control rate (DCR) observed with combination therapy Initial Part C efficacy observations align with previously reported THIO-101 clinical activity despite a more heavily pre-treated patient population CHICAGO, July 08, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced positive initial efficacy data from its Phase 2 THIO-101 clinical trial expansion, Part C, evaluating its lead candidate, ateganosine, a dual mechanism of action drug incorporating telomere targeting and immunogenicity, as a third-line (3L) therapy for patients with advanced non-small cell lung cancer (NSCLC).
MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer
Part C domestic enrollment is underway at three clinical sites in the U.S. CHICAGO, June 25, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has completed international enrollment in Part C of its Phase 2 THIO-101 expansion trial evaluating its lead candidate, ateganosine, in advanced non-small cell lung cancer (NSCLC) patients receiving third line (3L) therapy. Ateganosine is an investigational dual-mechanism therapy targeting telomeres and immune activation in difficult-to-treat cancers.
